Drugs / anti-CD19 CAR-T
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03110640 | Oct 2016 → Jun 2020 | B-cell adult acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia | First Affiliated Hospital of Wenzhou Medical University | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04196205 | Dec 2019 → Aug 2020 | acute lymphoblastic leukemia | The First Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02685670 | Feb 2016 → Dec 2017 | B-cell adult acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110640 ↗ |
| Modality | Cell therapy | “αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells” NCT02685670 ↗ |
| Target | CD19 | “CD19-specific chimeric antigen receptor (CD19CAR)” NCT02685670 ↗ |